Organization

Data from Myriad Genetics offered early validation evidence for an expanded version of its commercial test, as well as a look into clinical impact via claims data.

Mansinh Chaudhari purchased Medicare beneficiary information and sold it to healthcare providers who then submitted unnecessary COVID-19 tests for those beneficiaries.

The company has requested a hearing and paid a $20,000 fee to delay its delisting determination until Jan. 9, 2025.